EGFR and neoplasm: Osimertinib has greater penetration of the mouse blood–brain barrier than gefitinib, rociletinib, or afatinib, and induced sustained tumor regression in an EGFR mutant PC9 mouse brain metastasis model at clinically relevant doses, while rociletinib did not achieve tumor regression (55).